Aldehyde dehydrogenase-2 protects against myocardial infarction-related cardiac fibrosis through modulation of the Wnt/β-catenin signaling pathway

被引:37
|
作者
Zhao, Xinjun [1 ,2 ]
Hua, Yue [1 ,2 ]
Chen, Hongmei [1 ,2 ]
Yang, Haiyu [3 ]
Zhang, Tao [1 ,2 ]
Huang, Guiqiong [4 ]
Fan, Huijie [1 ,2 ]
Tan, Zhangbin [1 ,2 ]
Huang, Xiaofang [1 ,2 ]
Liu, Bin [5 ]
Zhou, Yingchun [1 ,2 ]
机构
[1] Southern Med Univ, Key Lab Mol Biol, State Adm Tradit Chinese Med, Sch Tradit Chinese Med, Guangzhou, Guangdong, Peoples R China
[2] Southern Med Univ, Nanfang Hosp, Guangzhou Ave North 1838, Guangzhou 510515, Guangdong, Peoples R China
[3] Jiangmen Wuyi Tradit Chinese Med Hosp, Jiangmen, Guangdong, Peoples R China
[4] Huizhou Hosp Tradit Chinese Med, Huizhou, Peoples R China
[5] Guangzhou Med Univ, Affiliated Hosp 2, Guangzhou, Guangdong, Peoples R China
基金
中国博士后科学基金;
关键词
myocardial infarction; aldehyde dehydrogenase; cardiac fibrosis; Wnt signaling; HEART-FAILURE; RAT MODEL; ACTIVATION; OVEREXPRESSION; MYOFIBROBLASTS; DISEASE; UPDATE; WNT;
D O I
10.2147/TCRM.S88297
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background: Aldehyde dehydrogenase-2 (ALDH2) has a protective effect on ischemic heart disease. Here, we examined the protective effects of ALDH2 on cardiac fibrosis through modulation of the Wnt/beta-catenin signaling pathway in a rat model of myocardial infarction (MI). Methods: Wistar rats were divided into the sham (control), MI (model), and ALDH2 activator (Alda-1) groups. After 10 days of treatment, the left ventricular (LV) remodeling parameters of each animal were evaluated by echocardiography. Myocardial fibrosis was evaluated by Masson's trichrome staining and Sirius Red staining. Expression levels of collagen types I and III and alpha-smooth muscle actin (alpha-SMA) were examined. Finally, the expression and activity of ALDH2 and the levels of several Wnt-related proteins and genes, such as phospho-glycogen synthase kinase (GSK)-3 beta, GSK-3 beta, beta-catenin, Wnt-1, WNT1-inducible signaling-pathway protein 1, and tumor necrosis factor (TNF)-alpha, were also analyzed. Results: After MI, the heart weight/body weight ratio, LV dimension at end diastole, and LV dimension at end systole were decreased, while the LV ejection fraction and LV fractional shortening were increased in the Alda-1 group. Myocardial fibrosis was also reduced in the Alda-1 group, accompanied by decreased expression collagen types I and III and alpha-SMA. beta-Catenin, phosphorylated GSK-3 beta, and Wnt-1 levels were significantly increased in the model group. Interestingly, this alteration was partly reversed by Alda-1 treatment. Immunohistochemical staining showed that numerous WNT1-inducible signaling-pathway protein 1 (WISP-1)- and TNF-alpha-positive cells were found in the model group. However, few WISP-1- and TNF-alpha-positive cells were detected in the Alda-1 group. Conclusion: The reduction of cardiac fibrosis and the down-regulation of beta-catenin, phosphorylated GSK-3 beta, Wnt-1, and WISP-1 may be mediated by increased ALDH2 activity, leading to reduction of MI-related cardiac fibrosis.
引用
收藏
页码:1371 / 1381
页数:11
相关论文
共 50 条
  • [1] Aldehyde dehydrogenase 2 protects against sympathetic excitationinduced cardiac fibrosis
    Yuan, Qiuhuan
    Yang, Feihong
    Dai, Shuai
    Wang, Zheng
    Xu, Youshun
    Xu, Bai-Chao
    Sun, Yi
    Zheng, Boyuan
    Zhao, Yu
    Wang, Wenjun
    Liu, Baoshan
    Wang, Jiali
    Cui, Sumei
    Cao, Shengchuan
    Zhang, Rui
    Xue, Li
    Wei, Shujian
    Xue, Mengyang
    Xu, Tonghui
    Xu, Feng
    Chen, Yuguo
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2020, 533 (04) : 1427 - 1434
  • [2] Sinensetin protects against pulmonary fibrosis via inhibiting Wnt/?-Catenin signaling pathway
    Wan, Xuan
    Chen, Shuyun
    Li, Penghui
    Zhao, Tiantian
    Xie, Shiguang
    Fang, Yan
    TISSUE & CELL, 2022, 78
  • [3] Molecular mechanism of triptolide in myocardial fibrosis through the Wnt/β-catenin signaling pathway
    Zhang, Yiwen
    Lu, Feng
    SCANDINAVIAN CARDIOVASCULAR JOURNAL, 2024, 58 (01)
  • [4] Lcz696 Alleviates Myocardial Fibrosis After Myocardial Infarction Through the sFRP-1/Wnt/β-Catenin Signaling Pathway
    Liu, Jing
    Zheng, Xuehui
    Zhang, Chen
    Zhang, Chunmei
    Bu, Peili
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [5] Sclerostin aggravates cardiac remodeling after myocardial infarction by inhibition of Wnt/β-catenin signaling pathway
    Zheng, Shuxin
    Wei, Jinyi
    Chen, Peipei
    Chen, Fangliang
    Yang, Guang
    JOURNAL OF THORACIC DISEASE, 2022, 14 (05) : 1563 - +
  • [6] Andrographolide Protects Against Adverse Cardiac Remodeling After Myocardial Infarction through Enhancing Nrf2 Signaling Pathway
    Xie, Saiyang
    Deng, Wei
    Chen, Jiaojiao
    Wu, Qing-Qing
    Li, Hongjian
    Wang, Juan
    Wei, Li
    Liu, Chen
    Duan, Mingxia
    Cai, Zhulan
    Xie, Qingwen
    Hu, Tongtong
    Zeng, Xiaofeng
    Tang, Qizhu
    INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, 2020, 16 (01): : 12 - 26
  • [7] Secreted frizzled-related protein 5 protects against renal fibrosis by inhibiting Wnt/β-catenin pathway
    Deng, Dai
    Tian, Dongli
    Wang, Yahui
    Bai, Yu
    Diao, Zongli
    Liu, Wenhu
    OPEN MEDICINE, 2024, 19 (01):
  • [8] Influence of MiR-154 on myocardial apoptosis in rats with acute myocardial infarction through Wnt/β-catenin signaling pathway
    Sun, H-Y
    Wang, X-L
    Ma, L-C
    Yang, M.
    Yang, H-J
    Huang, H-W
    Zhao, G-A
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2019, 23 (02) : 818 - 825
  • [9] Liquiritin Protects Against Cardiac Fibrosis After Myocardial Fibrosis After Myocardial Infarction by Inhibiting CCL5 Expression and the NF-κB Signaling Pathway [Letter]
    Idrus, Hasta Handayani
    Sunarno
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2023, 17 : 331 - 332
  • [10] Liquiritin Protects Against Cardiac Fibrosis After Myocardial Infarction by Inhibiting CCL5 Expression and the NF-ΚB Signaling Pathway
    Han, Xue
    Yang, Yakun
    Zhang, Muqing
    Li, Li
    Xue, Yucong
    Jia, Qingzhong
    Wang, Xiangting
    Guan, Shengjiang
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2022, 16 : 4111 - 4125